Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Table 3 Follow-up for inflammatory markers

Outcomes	Crude analysis		p-value^{^}	Beta coefficient (estimates) (95% CI)	p-value^$*
Outcomes	Control group	Tocilizumab group	p-value^{^}	Beta coefficient (estimates) (95% CI)	p-value^$*
Serum iron level follow-up, Median (Q1, Q3)	5.88 (3.70, 10.23)	8.91 (3.98, 13.66)	0.004	0.31 (0.15, 0.47)	0.0002
D-dimer level follow-up (mg/l), Median (Q1, Q3)	3.24 (1.13, 8.51)	4.01 (1.53,14.74)	0.006	2.81 (2.39, 3.24)	< 0.0001
Fibrinogen level follow-up (gm/l), Median (Q1, Q3)	6.29 (4.59, 7.85)	5.43 (3.60, 7.30)	0.0003	− 0.18 (− 0.28, − 0.08)	0.0002
CRP level follow-up (mg/l), Median (Q1, Q3)	164.0 (84.0, 261.0)	187.0 (93.0, 302.0)	0.14	0.11 (− 0.05, 0.27)	0.18
Procalcitonin level follow-up (ng/ml), Median (Q1, Q3)	0.46 (0.13, 1.73)	0.55 (0.15, 3.32)	0.09	− 0.37 (− 1.77, 1.03)	0.60

^{^}Wilcoxon rank sum test is used to calculate the p-value
^$* Multivariate Logistic regression is used after adjusting for patient’s age, SOFA score, PaO₂/FiO₂ ratio baseline and systemic corticosteroids during ICU stay to calculate estimates and p-value

ISSN: 1471-2334